SciClone Pharmaceuticals Newswire

SciClone Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for SciClone Pharmaceuticals.

Results 1 - 20 of 144 in SciClone Pharmaceuticals

  1. Corcept Therapeutics (CORT) & SciClone Pharmaceuticals (SCLN) Head to Head SurveyRead the original story w/Photo

    15 hrs ago | The Breeze

    Corcept Therapeutics and SciClone Pharmaceuticals are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. 64.7% of Corcept Therapeutics shares are held by institutional investors.

    Comment?

  2. Critical Review: Horizon PharmaRead the original story w/Photo

    16 hrs ago | Daily Political

    Horizon Pharma and SciClone Pharmaceuticals are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. SciClone Pharmaceuticals has lower revenue, but higher earnings than Horizon Pharma.

    Comment?

  3. Head-To-Head Comparison: Corcept TherapeuticsRead the original story w/Photo

    Tuesday Dec 12 | AmericanBankingNews.com

    Corcept Therapeutics and SciClone Pharmaceuticals are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. This is a summary of current recommendations and price targets for Corcept Therapeutics and SciClone Pharmaceuticals, as provided by MarketBeat.com.

    Comment?

  4. Bristol-Myers Squibb (BMY) versus SciClone Pharmaceuticals (SCLN) Head-To-Head ReviewRead the original story w/Photo

    Saturday Dec 9 | IntersportsWire

    Bristol-Myers Squibb and SciClone Pharmaceuticals are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership. This is a summary of current recommendations and price targets for Bristol-Myers Squibb and SciClone Pharmaceuticals, as provided by MarketBeat.com.

    Comment?

  5. Analyzing SciClone PharmaceuticalsRead the original story w/Photo

    Wednesday Dec 6 | AmericanBankingNews.com

    SciClone Pharmaceuticals and Bristol-Myers Squibb are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership. 72.8% of SciClone Pharmaceuticals shares are held by institutional investors.

    Comment?

  6. SciClone Pharmaceuticals (SCLN) and BioDelivery Sciences International (BDSI) Financial ContrastRead the original story w/Photo

    Tuesday Dec 5 | Daily Political

    SciClone Pharmaceuticals and BioDelivery Sciences International are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability. SciClone Pharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 25.56%.

    Comment?

  7. Comparing SciClone PharmaceuticalsRead the original story w/Photo

    Thursday Nov 30 | AmericanBankingNews.com

    SciClone Pharmaceuticals and BioDelivery Sciences International are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. This is a summary of recent recommendations and price targets for SciClone Pharmaceuticals and BioDelivery Sciences International, as provided by MarketBeat.com.

    Comment?

  8. Crossmark Global Holdings Inc. Acquires Shares of 27,770 SciClone Pharmaceuticals, Inc.Read the original story w/Photo

    Tuesday Nov 28 | Daily Political

    Crossmark Global Holdings Inc. acquired a new stake in SciClone Pharmaceuticals, Inc. during the third quarter, according to its most recent filing with the SEC. The firm acquired 27,770 shares of the specialty pharmaceutical company's stock, valued at approximately $311,000.

    Comment?

  9. FNY Partners Fund LP Has $3.76 Million Stake in SciClone Pharmaceuticals, Inc.Read the original story w/Photo

    Monday Nov 27 | IntersportsWire

    FNY Partners Fund LP increased its holdings in SciClone Pharmaceuticals, Inc. by 4,098.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 335,900 shares of the specialty pharmaceutical company's stock after buying an additional 327,900 shares during the period.

    Comment?

  10. Comparing SciClone PharmaceuticalsRead the original story w/Photo

    Sunday Nov 26 | Daily Political

    SciClone Pharmaceuticals and Tetraphase Pharmaceuticals are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. 72.8% of SciClone Pharmaceuticals shares are owned by institutional investors.

    Comment?

  11. SciClone Pharmaceuticals, Inc. (SCLN) Holdings Increased by Voya Investment Management LLCRead the original story w/Photo

    Nov 15, 2017 | Daily Political

    Voya Investment Management LLC boosted its position in SciClone Pharmaceuticals, Inc. by 12.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 27,747 shares of the specialty pharmaceutical company's stock after acquiring an additional 3,157 shares during the period.

    Comment?

  12. California Public Employees Retirement System Grows Position in SciClone Pharmaceuticals, Inc.Read the original story w/Photo

    Nov 14, 2017 | IntersportsWire

    California Public Employees Retirement System boosted its position in shares of SciClone Pharmaceuticals, Inc. by 3.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 83,700 shares of the specialty pharmaceutical company's stock after purchasing an additional 2,800 shares during the period.

    Comment?

  13. Somewhat Favorable Media Coverage Somewhat Unlikely to Impact...Read the original story w/Photo

    Nov 11, 2017 | Daily Political

    News articles about SciClone Pharmaceuticals have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time.

    Comment?

  14. UBS Asset Management Americas Inc. Maintains Holdings in SciClone Pharmaceuticals, Inc.Read the original story w/Photo

    Nov 8, 2017 | Daily Political

    UBS Asset Management Americas Inc. continued to hold its position in SciClone Pharmaceuticals, Inc. during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,297 shares of the specialty pharmaceutical company's stock at the close of the second quarter.

    Comment?

  15. Northern Trust Corp Grows Position in SciClone Pharmaceuticals, Inc.Read the original story w/Photo

    Nov 8, 2017 | IntersportsWire

    Northern Trust Corp increased its position in SciClone Pharmaceuticals, Inc. by 5.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission . The firm owned 849,629 shares of the specialty pharmaceutical company's stock after acquiring an additional 44,095 shares during the period.

    Comment?

  16. Fox Run Management L.L.C. Invests $321,000 in SciClone Pharmaceuticals, Inc. (SCLN) StockRead the original story w/Photo

    Nov 3, 2017 | IntersportsWire

    Fox Run Management L.L.C. purchased a new position in SciClone Pharmaceuticals, Inc. during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 28,700 shares of the specialty pharmaceutical company's stock, valued at approximately $321,000.

    Comment?

  17. Financial Comparison: SciClone Pharmaceuticals (SCLN) & The CompetitionRead the original story w/Photo

    Nov 2, 2017 | AmericanBankingNews.com

    SciClone Pharmaceuticals is one of 116 publicly-traded companies in the "Pharmaceuticals" industry, but how does it weigh in compared to its competitors? We will compare SciClone Pharmaceuticals to similar businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. 72.8% of SciClone Pharmaceuticals shares are owned by institutional investors.

    Comment?

  18. SciClone Pharmaceuticals, Inc. (SCLN) to Release Earnings on TuesdayRead the original story w/Photo

    Oct 31, 2017 | AmericanBankingNews.com

    SciClone Pharmaceuticals, Inc. is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect SciClone Pharmaceuticals to post earnings of $0.22 per share for the quarter.

    Comment?

  19. Somewhat Favorable News Coverage Somewhat Unlikely to Impact SciClone ...Read the original story w/Photo

    Oct 30, 2017 | Daily Political

    Media coverage about SciClone Pharmaceuticals has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time.

    Comment?

  20. SciClone Pharmaceuticals, Inc. (SCLN) Shares Bought by Goldman Sachs Group Inc.Read the original story w/Photo

    Oct 27, 2017 | IntersportsWire

    Goldman Sachs Group Inc. raised its stake in SciClone Pharmaceuticals, Inc. by 45.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 330,655 shares of the specialty pharmaceutical company's stock after buying an additional 103,534 shares during the period.

    Comment?